Identification of Information Flow‐Modulating Drug Targets: A Novel Bridging Paradigm for Drug Discovery

Our objective in this study was to identify novel metrics for efficient identification of drug targets using biological network topology data. We developed a novel paradigm and metric, namely, bridging centrality, capable of identifying nodes critically involved in connecting or bridging modular subregions of a network. The topological and biological characteristics of bridging nodes were delineated in a diverse group of published yeast networks and in three human networks: those involved in cardiac arrest, C21‐steroid hormone biosynthesis, and steroid biosynthesis. The bridging centrality metric was highly selective for bridging nodes. Bridging nodes differed distinctively from nodes with high degree and betweenness centrality. Bridging nodes had lower lethality, and their gene expression was consistent with independent regulation. Analysis of biological correlates indicated that bridging nodes are promising drug targets from the standpoints of efficacy and side effects. The bridging centrality method is a promising computational systems biology tool to aid target identification in drug discovery.

[1]  Gert Sabidussi,et al.  The centrality index of a graph , 1966 .

[2]  Leonard M. Freeman,et al.  A set of measures of centrality based upon betweenness , 1977 .

[3]  P. Bonacich.  Power and Centrality: A Family of Measures , 1987, American Journal of Sociology.

[4]  Michael Ruogu Zhang,et al.  Comprehensive identification of cell cycle-regulated genes of the yeast Saccharomyces cerevisiae by microarray hybridization. , 1998, Molecular biology of the cell.

[5]  Y. Yazaki,et al.  The molecular mechanism of cardiac hypertrophy and failure. , 1998, Annals of the New York Academy of Sciences.

[6]  M. Ghannoum,et al.  Antifungal Agents: Mode of Action, Mechanisms of Resistance, and Correlation of These Mechanisms with Bacterial Resistance , 1999, Clinical Microbiology Reviews.

[7]  I. Abe,et al.  Green tea polyphenols: novel and potent inhibitors of squalene epoxidase. , 2000, Biochemical and biophysical research communications.

[8]  Albert-László Barabási,et al.  Error and attack tolerance of complex networks , 2000, Nature.

[9]  M. Ashburner,et al.  Gene Ontology: tool for the unification of biology , 2000, Nature Genetics.

[10]  Y. Zou,et al.  Isoproterenol Activates Extracellular Signal–Regulated Protein Kinases in Cardiomyocytes Through Calcineurin , 2001, Circulation.

[11]  A. Chugh,et al.  Squalene epoxidase as hypocholesterolemic drug target revisited. , 2003, Progress in lipid research.

[12]  Q. Ouyang,et al.  The yeast cell-cycle network is robustly designed. , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[13]  A. Chakravarti,et al.  Genomics in sudden cardiac death. , 2004, Circulation research.

[14]  Lan V. Zhang,et al.  Evidence for dynamically organized modularity in the yeast protein–protein interaction network , 2004, Nature.

[15]  M. Egger,et al.  Risk of cardiovascular events and rofecoxib: cumulative meta-analysis , 2004, The Lancet.

[16]  Mark E. J. Newman.  A measure of betweenness centrality based on random walks , 2005, Soc. Networks.

[17]  Matthew W. Hahn,et al.  Comparative genomics of centrality and essentiality in three eukaryotic protein-interaction networks. , 2005, Molecular biology and evolution.

[18]  T. Sugiyama,et al.  Aldosterone induces angiotensin converting enzyme gene expression via a JAK2-dependent pathway in rat endothelial cells. , 2005, Endocrinology.

[19]  J. A. Rodríguez-Velázquez,et al.  Subgraph centrality in complex networks. , 2005, Physical review. E, Statistical, nonlinear, and soft matter physics.

[20]  A. Giuliani,et al.  Functional essentiality from topology features in metabolic networks: A case study in yeast , 2005, FEBS letters.

[21]  M. Burnier.  The safety of rofecoxib , 2005, Expert opinion on drug safety.

[22]  R. Guimerà,et al.  Functional cartography of complex metabolic networks , 2005, Nature.

[23]  Dmitrij Frishman,et al.  MIPS: analysis and annotation of proteins from whole genomes in 2005 , 2006, Nucleic Acids Res..

[24]  F. Barkhof,et al.  Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. , 2006, The New England journal of medicine.

[25]  M. Caulfield,et al.  Effects of torcetrapib in patients at high risk for coronary events. , 2007, The New England journal of medicine.

[26]  B. Coulombe.  Faculty Opinions recommendation of The importance of bottlenecks in protein networks: correlation with gene essentiality and expression dynamics. , 2007 .

[27]  Mark Gerstein,et al.  The Importance of Bottlenecks in Protein Networks: Correlation with Gene Essentiality and Expression Dynamics , 2007, PLoS Comput. Biol..

[28]  L. Hedges,et al.  Cumulative Meta‐Analysis , 2009 .